アンチセンスオリゴヌクレオチド（ASO）治療薬市場レポート：2023-2033

Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033

レポート詳細アンチセンスオリゴヌクレオチド（ASO）治療薬市場レポート 2023-2033年：本レポートは、業界とその基礎となるダイナミクスをより良く理解したい場合、新たな収益ポケットを目指してい... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
Visiongain ヴィジョンゲイン社	2023年10月20日	GBP4,500 部署ライセンスライセンス・価格情報注文方法はこちら	286	258	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

目次
図表リスト

サマリー

レポート詳細

アンチセンスオリゴヌクレオチド（ASO）治療薬市場レポート 2023-2033年：本レポートは、業界とその基礎となるダイナミクスをより良く理解したい場合、新たな収益ポケットを目指している大手企業にとって非常に貴重なものとなります。異業種への進出や、新たな地域での既存事業の拡大を目指す企業にとっても有用です。

希少疾患治療へのASO治療薬の採用が市場成長を牽引
アンチセンスオリゴヌクレオチド（ASO）の希少遺伝性疾患治療への応用は、この治療アプローチの変革力を示す説得力のある証である。希少疾患は、しばしば希少疾病と呼ばれ、人口における有病率が低いという特徴があるため、従来の医薬品開発にはあまり魅力的ではありませんでした。しかし、ASOはこれらの疾患に苦しむ人々にとって希望の光として登場し、ASOの研究開発に大きな関心と投資を促している。

希少疾患の場合、従来の医薬品開発経路はしばしば大きなハードルに直面する。患者数が少ないため、大規模な臨床試験を実施することは困難であり、このような疾患に対する医薬品開発の財政的な実行可能性には疑問が残る。ASOは、その精度と適応性により、これらの課題に対処するための新たな可能性を切り開いた。

ASOは、希少疾患の原因となる特定の遺伝子変異や異常を標的とするよう調整することができる。この個別化されたアプローチにより、単に症状を管理するのではなく、症状の根本的な原因に直接対処する治療法の開発が可能になる。このことは、希少疾患の治療状況を一変させる可能性を秘めており、これまで存在しなかった効果的な疾患修飾的治療法の可能性を提供するものである。

一部の患者における免疫原性反応の可能性が業界の成長を阻む可能性
アンチセンスオリゴヌクレオチド（ASO）治療薬市場では、免疫原性が大きな市場阻害要因となっている。ASOはさまざまな疾患の治療において大きな可能性を秘めていますが、患者によっては免疫反応を引き起こす可能性があるため、副作用や治療効果の低下につながる可能性があります。この免疫原性反応は、ASO療法の普及を妨げ、患者の安全性と規制当局の承認という点で課題をもたらす可能性がある。この懸念を軽減するため、ASO分子の免疫原性を低減するための化学修飾や構造変化に焦点を当てた広範な研究開発が行われてきた。

市場調査レポートを購入する前にすべき質問とは？
- アンチセンスオリゴヌクレオチド（ASO）治療薬市場はどのように進化しているのか？
- アンチセンスオリゴヌクレオチド（ASO）治療薬市場の促進要因と抑制要因は何か？
- アンチセンスオリゴヌクレオチド（ASO）治療薬の各サブマーケットセグメントは予測期間中にどのように成長し、これらのサブマーケットが2033年にどれくらいの収益を占めるのか？
- 2023年から2033年にかけて、アンチセンスオリゴヌクレオチド（ASO）治療薬の各サブマーケットの市場シェアはどのように推移するのか？
- 2023年から2033年にかけての市場全体の主な牽引役は何か？
- 主要なアンチセンスオリゴヌクレオチド（ASO）治療薬市場はマクロ経済力学に広く追随するのか、それとも個々の国市場が他を凌駕するのか？
- 2033年までに各国市場のシェアはどのように変化し、どの地域が2033年に市場をリードするのか？
- 主要プレイヤーは誰で、予測期間中の見通しは？
- これら主要企業のアンチセンスオリゴヌクレオチド（ASO）治療薬プロジェクトとは？
- 2023年から2033年の間に、業界はどのように発展するのか？アンチセンス・オリゴヌクレオチド（ASO）治療薬プロジェクトは、現在および今後10年間にどのような意味を持つのでしょうか？
- アンチセンスオリゴヌクレオチド（ASO）治療薬市場をさらに拡大するために、製品の商業化の必要性は高まっているか？
- アンチセンスオリゴヌクレオチド（ASO）治療薬市場はどこに向かい、どのようにすれば市場の最前線に立てるのか？
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

アンチセンスオリゴヌクレオチド（ASO）治療薬市場が現在、そして今後10年間でどのような影響を受けるかを知る必要がある：
- 286ページにわたる本レポートでは、107の表と151の図表を掲載しています。
- 本レポートでは、業界における主要な有利分野を取り上げているため、今すぐターゲットを絞ることができます。
- 世界、地域、国の売上と成長に関する詳細な分析が含まれています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。

本レポートは、アンチセンスオリゴヌクレオチド（ASO）治療薬市場が今後10年間でどのように発展するか、またCOVID-19の景気後退と好転の変動に合わせてどのように発展するかをお伝えします。この市場は、過去10年間のどの時点よりも今が重要です。

2033年までの予測やその他の分析から、商業的な展望が明らかになる
- 2033年までの収益予測に加え、直近の業績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望と展開に関する独自の分析をご覧いただけます。
- 定性的分析（市場ダイナミクス、促進要因、機会、阻害要因、課題など）、コスト構造、アンチセンスオリゴヌクレオチド（ASO）治療薬価格上昇の影響、最近の動向などをご覧いただけます。

本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれている。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じている。

レポート対象セグメント

治療応用
- 神経疾患
- 遺伝子疾患
- 腫瘍学的疾患
- 心血管疾患
- その他

ASO化学
- DNAベースASO
- RNAベースASO
- ギャップマーASO

投与経路
- 肺投与
- 静脈内注射
- 皮内注射
- 腹腔内注射
- 局所投与
- その他

世界市場全体と各分野の収益予測に加え、5つの地域と24の主要国市場の収益予測も掲載している：

北米
- アメリカ
- カナダ

欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他の欧州

アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- シンガポール
- その他のアジア太平洋地域

ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- コロンビア
- その他のラテンアメリカ

MEA
- GCC
- 南アフリカ
- その他のMEA

また、アンチセンスオリゴヌクレオチド（ASO）治療薬市場の2023年から2033年にかけての主要企業のプロファイルと、これらの企業の事業のこのセグメントに焦点を当てています。

主要企業と市場成長の可能性
・ Alector, Inc.
・ Alnylam Pharmaceuticals, Inc.
・ Antisense Therapeutics Limited
・ Arrowhead Pharmaceuticals, Inc.
・ Biogen
・ Bio-Path Holdings
・ Dicerna Pharmaceuticals, Inc.
・ Geron Corporation (Geron)
・ GSK plc
・ iCo Therapeutics Inc.
・ Ionis Pharmaceuticals, Inc.
・ ProQR Therapeutics
・ Roche Holding AG
・ Sarepta Therapeutics
・ Sterna Biologicals

アンチセンスオリゴヌクレオチド（ASO）治療薬市場の2023年から2033年にかけての世界全体の売上高は、金額ベースでは2023年に60億米ドルを超えるだろうと、当研究所では計算しています。2033年まで力強い収益成長を予測。当研究所では、最も大きな可能性を秘めた組織を特定しています。彼らの能力、進歩、商業的展望を発見し、一歩先を行くお手伝いをします。

アンチセンスオリゴヌクレオチド（ASO）治療薬市場、2023～2033年レポートはどのようにお役に立ちますか？
要約すると、280ページを超えるこのレポートは、以下の知識を提供する：

- アンチセンスオリゴヌクレオチド（ASO）治療薬市場の2023年から2033年までの収益予測治療用途、ASOケミストリー、投与経路の各予測を世界レベルと地域レベルで掲載 - 業界の将来性を発見し、投資と収益に最も有利な場所を見つけます。

- 5つの地域と24の主要国市場の2033年までの収益予測 - アンチセンスオリゴヌクレオチド（ASO）治療薬市場、北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEAの2023年から2033年までの市場予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの著名経済圏の市場も予測しています。

- 既存企業や市場参入を目指す企業の展望 - アンチセンスオリゴヌクレオチド（ASO）治療薬市場に関わる主要企業15社の企業プロファイルを含む、2023年から2033年までの市場。

独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。

他にはない情報
私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。Visiongainの調査レポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、アンチセンスオリゴヌクレオチド（ASO）治療薬市場、2023年～2033年、市場をリードする企業の商業分析を必要とするすべての人のためのものです。データ、動向、予測をご覧いただけます。

ページTOPに戻る

1 レポート概要
1.1 研究の目的
1.2 アンチセンスオリゴヌクレオチド（ASO）治療薬市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問
1.6 本レポートは誰のためのものか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ）
1.9 Visiongainの関連レポート
1.10 Visiongainについて

2 エグゼクティブ・サマリー

3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場牽引要因
3.2.1.1 ASO治療薬市場を牽引する標的特異的精密医療分野の発展
3.2.1.2 希少疾患治療へのASO治療薬の採用がASO治療薬市場を牽引
3.2.1.3 ASOの可能性を最大限に引き出すデリバリーシステムの改良が市場を後押し
3.2.2 市場抑制要因
3.2.2.1 オフターゲット効果はASO治療薬の開発と採用における重大な市場抑制要因になる可能性がある
3.2.2.2 一部の患者における免疫原性反応の可能性がASO治療薬市場の成長を抑制する可能性
3.2.2.3 ASO治療薬の治療・製造コストの高さが市場成長に悪影響を及ぼす可能性
3.2.3 市場機会
3.2.3.1 ASO治療薬に有望な市場機会を提供するかもしれない癌治療への新規アプローチ
3.2.3.2 ASO治療薬の領域では、パイプラインの拡充が重要な市場機会として立ちはだかる
3.2.3.3 ASO治療薬の領域では、規制当局の支援の有無が大きな市場可能性
3.3 COVID-19の影響分析
3.4 ポーターのファイブフォース分析
3.4.1 サプライヤーの交渉力
3.4.2 買い手の交渉力
3.4.3 競争相手のライバル関係
3.4.4 代替品による脅威
3.4.5 新規参入企業の脅威
3.5 PEST分析

4 アンチセンスオリゴヌクレオチド（ASO）治療薬市場分析：治療用途別
4.1 主要な調査結果
4.2 治療用途セグメント市場魅力度指数
4.3 アンチセンスオリゴヌクレオチド（ASO）治療薬の治療用途別市場規模推定と予測
4.4 神経疾患
4.4.1 2023〜2033年の地域別市場規模（US$ Million）
4.4.2 地域別市場シェア、2023年・2033年 (%)
4.5 遺伝子疾患
4.5.1 2023〜2033年の地域別市場規模（US$ Million）
4.5.2 地域別市場シェア、2023年・2033年 (%)
4.6 腫瘍性疾患
4.6.1 2023〜2033年の地域別市場規模（US$ Million）
4.6.2 地域別市場シェア、2023年・2033年 (%)
4.7 循環器疾患
4.7.1 2023〜2033年の地域別市場規模（US$ Million）
4.7.2 地域別市場シェア、2023年・2033年 (%)
4.8 その他
4.8.1 2023〜2033年の地域別市場規模（US$ Million）
4.8.2 地域別市場シェア、2023年・2033年 (%)

5 アンチセンスオリゴヌクレオチド（ASO）治療薬市場分析：ASO化学別
5.1 主な調査結果
5.2 ASO化学セグメント市場魅力度指数
5.3 アンチセンスオリゴヌクレオチド（ASO）治療薬のASO化学別市場規模推定と予測
5.4 DNAベースのASO
5.4.1 2023〜2033年の地域別市場規模（US$ Million）
5.4.2 地域別市場シェア、2023年・2033年 (%)
5.5 RNAベースASO
5.5.1 2023〜2033年の地域別市場規模（US$ Million）
5.5.2 地域別市場シェア、2023年・2033年 (%)
5.6 ギャッパーASO
5.6.1 2023～2033年の地域別市場規模（US$ Million）
5.6.2 地域別市場シェア、2023年・2033年 (%)

6 アンチセンスオリゴヌクレオチド（ASO）治療薬市場分析：投与経路別
6.1 主要調査結果
6.2 投与経路セグメント市場魅力度指数
6.3 アンチセンスオリゴヌクレオチド（ASO）治療薬の投与経路別市場規模推定と予測
6.4 肺送達
6.4.1 2023〜2033年の地域別市場規模（US$ Million）
6.4.2 地域別市場シェア、2023年・2033年 (%)
6.5 静脈注射剤
6.5.1 2023～2033年の地域別市場規模（US$ Million）
6.5.2 地域別市場シェア、2023年・2033年 (%)
6.6 皮内注射剤
6.6.1 2023～2033年の地域別市場規模（US$ Million）
6.6.2 地域別市場シェア、2023年・2033年 (%)
6.7 腹腔内注射剤
6.7.1 2023～2033年の地域別市場規模（US$ Million）
6.7.2 地域別市場シェア、2023年・2033年 (%)
6.8 局所デリバリー
6.8.1 2023〜2033年の地域別市場規模（US$ Million）
6.8.2 地域別市場シェア、2023年・2033年 (%)
6.9 その他
6.9.1 2023〜2033年の地域別市場規模（US$ Million）
6.9.2 地域別市場シェア、2023年・2033年 (%)

7 アンチセンスオリゴヌクレオチド（ASO）治療薬市場分析：地域別
7.1 主要な調査結果
7.2 地域別市場規模の推定と予測

8 北米のアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
8.1 主要な調査結果
8.2 北米のアンチセンスオリゴヌクレオチド（ASO）治療薬市場魅力度指数
8.3 北米のアンチセンスオリゴヌクレオチド（ASO）治療薬国別市場、2023年、2028年、2033年 (US$ Million)
8.4 北米のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：国別
8.5 北米のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：治療用途別
8.6 北米のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：ASO化学別
8.7 北米のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：投与経路別
8.8 アメリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
8.9 カナダのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析

9 欧州のアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
9.1 主要な調査結果
9.2 欧州のアンチセンスオリゴヌクレオチド（ASO）治療薬市場魅力度指数
9.3 欧州のアンチセンスオリゴヌクレオチド（ASO）治療薬国別市場、2023年、2028年＆2033年 (US$ Million)
9.4 欧州のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：国別
9.5 欧州のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：治療用途別
9.6 欧州のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：ASO化学別
9.7 欧州のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：投与経路別
9.8 ドイツのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
9.9 フランスアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
9.10 イギリスアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
9.11 イタリアアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
9.12 スペインのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
9.13 ロシアのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
9.14 その他の欧州のアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析

10 アジア太平洋地域のアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
10.1 主要な調査結果
10.2 アジア太平洋地域のアンチセンスオリゴヌクレオチド（ASO）治療薬市場魅力度指数
10.3 アジア太平洋地域のアンチセンスオリゴヌクレオチド（ASO）治療薬国別市場、2023年、2028年、2033年 (US$ Million)
10.4 アジア太平洋地域のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：国別
10.5 アジア太平洋地域のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：治療用途別
10.6 アジア太平洋地域のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：ASO化学別
10.7 アジア太平洋地域のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：投与経路別
10.8 日本のアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
10.9 中国のアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
10.10 インドのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
10.11 オーストラリアのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
10.12 韓国のアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
10.13 シンガポールのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
10.14 その他のアジア太平洋地域のアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析

11 ラテンアメリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
11.1 主要な調査結果
11.2 ラテンアメリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場魅力度指数
11.3 ラテンアメリカのアンチセンスオリゴヌクレオチド（ASO）治療薬国別市場、2023年、2028年、2033年 (US$ Million)
11.4 ラテンアメリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：国別
11.5 ラテンアメリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：治療用途別
11.6 ラテンアメリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：ASO化学別
11.7 ラテンアメリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：投与経路別
11.8 ブラジルのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
11.9 メキシコのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
11.10 アルゼンチンのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
11.11 コロンビアのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
11.12 その他のラテンアメリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析

12 MEAアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
12.1 主要な調査結果
12.2 MEAのアンチセンスオリゴヌクレオチド（ASO）治療薬市場魅力度指数
12.3 MEAのアンチセンスオリゴヌクレオチド（ASO）治療薬国別市場：2023年、2028年、2033年（US$ Million）
12.4 MEAのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：国別
12.5 MEAのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：治療用途別
12.6 MEAのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：ASO化学別
12.7 MEAのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模推定と予測：投与経路別
12.8 GCCのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
12.9 南アフリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析
12.10 その他のMEAアンチセンスオリゴヌクレオチド（ASO）治療薬市場分析

13 企業のプロフィール
13.1 競争環境、2022年
13.2 戦略的展望
13.3 Biogen
13.3.1 会社概要
13.3.2 会社概要
13.3.3 財務分析
13.3.3.1 純収入、2017-2022年
13.3.3.2 売上総利益、2017-2022年
13.3.3.3 R＆D、2017-2022年
13.3.4 製品ベンチマーク
13.3.5 戦略的展望
13.4 Bio-Path Holdings
13.4.1 会社概要
13.4.2 会社概要
13.4.3 製品ベンチマーク
13.4.4 戦略的展望
13.5 Ionis Pharmaceuticals, Inc.
13.5.1 会社概要
13.5.2 会社概要
13.5.3 財務分析
13.5.3.1 純収入、2017-2022年
13.5.3.2 売上総利益、2017-2022年
13.5.3.3 R＆D、2017-2022年
13.5.4 製品ベンチマーク
13.5.5 戦略的展望
13.6 ProQR Therapeutics
13.6.1 会社概要
13.6.2 会社概要
13.6.3 製品ベンチマーク
13.6.4 戦略的展望
13.7 Sarepta Therapeutics
13.7.1 会社概要
13.7.2 会社概要
13.7.3 財務分析
13.7.3.1 純収入、2017-2022年
13.7.3.2 売上総利益、2017-2022年
13.7.3.3 R＆D、2017-2022年
13.7.4 製品ベンチマーク
13.7.5 戦略的展望
13.8 Alnylam Pharmaceuticals, Inc.
13.8.1 会社概要
13.8.2 会社概要
13.8.3 財務分析
13.8.3.1 純収入、2017-2022年
13.8.3.2 売上総利益、2017-2022年
13.8.3.3 R＆D、2017-2022年
13.8.4 製品ベンチマーク
13.8.5 戦略的展望
13.9 Arrowhead Pharmaceuticals, Inc.
13.9.1 会社概要
13.9.2 会社概要
13.9.3 財務分析
13.9.3.1 純収入、2017-2022年
13.9.3.2 売上総利益、2017-2022年
13.9.3.3 R＆D、2017-2022年
13.9.4 製品ベンチマーク
13.9.5 戦略的展望
13.10 GSK plc
13.10.1 会社概要
13.10.2 会社概要
13.10.3 財務分析
13.10.3.1 純収入、2017-2022年
13.10.3.2 売上総利益、2017-2022年
13.10.3.3 R＆D、2017-2022年
13.10.4 製品ベンチマーク
13.11 Geron Corporation (Geron)
13.11.1 会社概要
13.11.2 会社概要
13.11.3 財務分析
13.11.3.1 純収入、2017-2022年
13.11.3.2 R＆D（2017年～2022年
13.11.4 製品ベンチマーク
13.12 Antisense Therapeutics Limited
13.12.1 会社概要
13.12.2 会社概要
13.12.3 財務分析
13.12.3.1 純収入、2017-2022年
13.12.3.2 R＆D、2017-2022年
13.12.4 製品ベンチマーク
13.12.5 戦略的展望
13.13 Sterna Biologicals
13.13.1 会社概要
13.13.2 会社概要
13.13.3 製品ベンチマーク
13.14 Alector, Inc.
13.14.1 会社概要
13.14.2 会社概要
13.14.3 製品ベンチマーク
13.14.4 戦略的展望
13.15 Dicerna Pharmaceuticals, Inc.
13.15.1 会社概要
13.15.2 会社概要
13.15.3 製品ベンチマーク
13.16 iCo Therapeutics Inc.
13.16.1 会社概要
13.16.2 会社概要
13.16.3 製品ベンチマーク
13.17 Roche Holding AG
13.17.1 会社概要
13.17.2 会社概要
13.17.3 財務分析
13.17.3.1 純収入、2017-2022年
13.17.3.2 売上高、2017-2022年
13.17.4 製品ベンチマーク

14 結論と提言
14.1 Visiongainからの結びの言葉
14.2 市場プレイヤーへの提言

ページTOPに戻る

図表リスト

表の一覧
Table 1 Antisense Oligonucleotide (ASO) Therapeutics Market Snapshot, 2023 & 2033 (US$ Million, CAGR %)
Table 2 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 7 Neurological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 8 Genetic Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 9 Oncological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 10 Cardiovascular Diseases Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 11 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 12 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 13 DNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 14 RNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 15 Gapmer ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 16 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 17 Pulmonary Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 18 Intravenous Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 19 Intradermal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 20 Intraperitoneal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 21 Topical Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 22 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 23 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 24 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 25 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 26 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 27 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 28 U.S. Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 29 Canada Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 30 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 31 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 32 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 33 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 34 Germany Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 35 France Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 36 UK Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 37 Italy Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 38 Spain Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 39 Russia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 40 Rest of Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 41 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 42 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 43 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 44 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 45 Japan Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 46 China Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 47 India Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 48 Australia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 49 South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 50 Singapore Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 51 Rest of Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 52 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 53 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 54 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 55 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 56 Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 57 Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 58 Argentina Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 59 Colombia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 60 Rest of Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 61 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 62 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 63 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 64 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 65 GCC Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 66 South Africa Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 67 Rest of MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 68 Strategic Outlook
Table 69 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Biogen: Product Benchmarking
Table 71 Biogen: Strategic Outlook
Table 72 Bio-Path Holdings: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Bio-Path Holdings: Product Benchmarking
Table 74 Bio-Path Holdings: Strategic Outlook
Table 75 Ionis Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Ionis Pharmaceuticals, Inc.: Product Benchmarking
Table 77 Ionis Pharmaceuticals, Inc.: Strategic Outlook
Table 78 ProQR Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 ProQR Therapeutics: Product Benchmarking
Table 80 ProQR Therapeutics: Strategic Outlook
Table 81 Sarepta Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Sarepta Therapeutics: Product Benchmarking
Table 83 Sarepta Therapeutics: Strategic Outlook
Table 84 Alnylam Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Alnylam Pharmaceuticals, Inc.: Product Benchmarking
Table 86 Alnylam Pharmaceuticals, Inc.: Strategic Outlook
Table 87 Arrowhead Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Arrowhead Pharmaceuticals, Inc.: Product Benchmarking
Table 89 Arrowhead Pharmaceuticals, Inc.: Strategic Outlook
Table 90 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 GSK plc: Product Benchmarking
Table 92 Geron Corporation (Geron): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Geron Corporation (Geron): Product Benchmarking
Table 94 Antisense Therapeutics Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Antisense Therapeutics Limited: Product Benchmarking
Table 96 Antisense Therapeutics Limited: Strategic Outlook
Table 97 Sterna Biologicals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Sterna Biologicals: Product Benchmarking
Table 99 Alector, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Alector, Inc.: Product Benchmarking
Table 101 Alector, Inc.: Strategic Outlook
Table 102 Dicerna Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Dicerna Pharmaceuticals, Inc.: Product Benchmarking
Table 104 iCo Therapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 iCo Therapeutics Inc.: Product Benchmarking
Table 106 Roche Holding AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Roche Holding AG: Product Benchmarking

図の一覧
Figure 1 Antisense Oligonucleotide (ASO) Therapeutics Market Segmentation
Figure 2 Antisense Oligonucleotide (ASO) Therapeutics Market by Therapeutic Application: Market Attractiveness Index
Figure 3 Antisense Oligonucleotide (ASO) Therapeutics Market by ASO Chemistry: Market Attractiveness Index
Figure 4 Antisense Oligonucleotide (ASO) Therapeutics Market by Route of Administration: Market Attractiveness Index
Figure 5 Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index by Region
Figure 6 Antisense Oligonucleotide (ASO) Therapeutics Market: Market Dynamics
Figure 7 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): “V” Shaped Recovery
Figure 8 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): “U” Shaped Recovery
Figure 9 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): “W” Shaped Recovery
Figure 10 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): “L” Shaped Recovery
Figure 11 Antisense Oligonucleotide (ASO) Therapeutics Market: Porter’s Five Forces Analysis
Figure 12 Antisense Oligonucleotide (ASO) Therapeutics Market: PEST Analysis
Figure 13 Antisense Oligonucleotide (ASO) Therapeutics Market by Therapeutic Application: Market Attractiveness Index
Figure 14 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 15 Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023, 2028, 2033 (%)
Figure 16 Neurological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 17 Neurological Disorders Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 18 Genetic Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 19 Genetic Disorders Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 20 Oncological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 21 Oncological Disorders Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Cardiovascular Diseases Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 23 Cardiovascular Diseases Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 25 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Antisense Oligonucleotide (ASO) Therapeutics Market by ASO Chemistry: Market Attractiveness Index
Figure 27 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 28 Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023, 2028, 2033 (%)
Figure 29 DNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 30 DNA Based ASO Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 31 RNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 32 RNA Based ASO Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 33 Gapmer ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 34 Gapmer ASO Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 35 Antisense Oligonucleotide (ASO) Therapeutics Market by Route of Administration: Market Attractiveness Index
Figure 36 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 37 Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023, 2028, 2033 (%)
Figure 38 Pulmonary Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 39 Pulmonary Delivery Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 40 Intravenous Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 41 Intravenous Injections Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 42 Intradermal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 43 Intradermal Injections Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 44 Intraperitoneal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 45 Intraperitoneal Injections Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 46 Topical Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 47 Topical Delivery Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 48 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 49 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 50 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region 2023 and 2033 (Revenue, CAGR%)
Figure 51 NASH DNA Based ASO & Therapeutics Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 52 NASH DNA Based ASO & Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %)
Figure 53 North America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 54 North America Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 55 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 56 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 57 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 58 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 59 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 60 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 61 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 62 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 63 U.S. Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 64 Canada Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 65 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 66 Europe Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 67 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 68 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 69 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 70 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 71 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 72 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 73 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 74 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 75 Germany Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 76 France Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 77 UK Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 78 Italy Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 79 Spain Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 80 Russia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 81 Rest of Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 82 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 83 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 84 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 85 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 86 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 87 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 88 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 89 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 90 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 91 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 92 Japan Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 93 China Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 94 India Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 95 Australia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 96 South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 97 Singapore Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 98 Rest of Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 99 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 100 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 101 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 102 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 103 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 104 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 105 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 106 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 107 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 108 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 109 Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 110 Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 111 Argentina Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 112 Colombia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 113 Rest of Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 114 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 115 MEA Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 116 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 117 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 118 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 119 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 120 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 121 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 122 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 123 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 124 GCC Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 125 South Africa Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 126 Rest of MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 127 Antisense Oligonucleotide (ASO) Therapeutics Market: Company Share/Ranking, 2022
Figure 128 Biogen: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 129 Biogen: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 130 Biogen: R&D, 2017-2022 (US$ Million, AGR %)
Figure 131 Ionis Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 132 Ionis Pharmaceuticals, Inc.: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 133 Ionis Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 134 Sarepta Therapeutics: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 135 Sarepta Therapeutics: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 136 Sarepta Therapeutics: R&D, 2017-2022 (US$ Million, AGR %)
Figure 137 Alnylam Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 138 Alnylam Pharmaceuticals, Inc.: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 139 Alnylam Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 140 Arrowhead Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 141 Arrowhead Pharmaceuticals, Inc.: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 142 Arrowhead Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 143 GSK plc: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 144 GSK plc: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 145 GSK plc: R&D, 2017-2022 (US$ Million, AGR %)
Figure 146 Geron Corporation (Geron): Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 147 Geron Corporation (Geron): R&D, 2017-2022 (US$ Million, AGR %)
Figure 148 Antisense Therapeutics Limited: Net Revenue, 2017-2022 (US$ Thousand, AGR%)
Figure 149 Antisense Therapeutics Limited: R&D, 2017-2022 (US$ Thousand, AGR%)
Figure 150 Roche Holding AG: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 151 Roche Holding AG: R&D, 2017-2022 (US$ Million, AGR %)

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Report Details

The Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Adoption of ASO Therapeutics for the Treatment of Rare Diseases Driving Market Growth
The application of antisense oligonucleotides (ASOs) in the treatment of rare genetic disorders is a compelling testament to the transformative power of this therapeutic approach. Rare diseases, often referred to as orphan diseases, are characterized by their low prevalence in the population, making them less attractive for traditional drug development efforts. However, ASOs have emerged as a ray of hope for individuals afflicted by these conditions, driving considerable interest and investment in ASO research and development.

Traditional drug development pathways often face significant hurdles when it comes to rare diseases. The small patient populations make conducting large-scale clinical trials challenging, and the financial viability of developing drugs for such conditions can be questionable. ASOs, with their precision and adaptability, have opened up new possibilities for addressing these challenges.

ASOs can be tailored to target the specific genetic mutations or abnormalities responsible for rare diseases. This personalized approach allows for the development of therapies that directly address the underlying cause of the condition, rather than just managing symptoms. This has the potential to revolutionize the treatment landscape for rare diseases, offering the prospect of effective, disease-modifying treatments where none existed before..

Potential Immunogenicity Response in Some Patients Likely to Challenge Industry Growth
Immunogenicity poses a significant market restraint for the antisense oligonucleotide (ASO) Therapeutics Market. While ASOs hold immense promise in treating a range of diseases, the potential to provoke an immune response in some patients can lead to adverse effects and reduced treatment effectiveness. This immunogenic response may hinder the widespread adoption of ASO therapies and pose challenges in terms of patient safety and regulatory approvals. To mitigate this concern, extensive research and development efforts have been focused on chemical modifications and structural alterations to ASO molecules to reduce their immunogenicity.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Antisense Oligonucleotide (ASO) Therapeutics market evolving?
• What is driving and restraining the Antisense Oligonucleotide (ASO) Therapeutics market?
• How will each Antisense Oligonucleotide (ASO) Therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each Antisense Oligonucleotide (ASO) Therapeutics submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading Antisense Oligonucleotide (ASO) Therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Antisense Oligonucleotide (ASO) Therapeutics projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of Antisense Oligonucleotide (ASO) Therapeutics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Antisense Oligonucleotide (ASO) Therapeutics market?
• Where is the Antisense Oligonucleotide (ASO) Therapeutics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Antisense Oligonucleotide (ASO) Therapeutics market today, and over the next 10 years:
• Our 286-page report provides 107 tables and 151 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Antisense Oligonucleotide (ASO) Therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Antisense Oligonucleotide (ASO) Therapeutics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Therapeutic Application
• Neurological Disorders
• Genetic Disorders
• Oncological Disorders
• Cardiovascular Diseases
• Others

ASO Chemistry
• DNA Based ASO
• RNA Based ASO
• Gapmer ASO

Route of Administration
• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Topical Delivery
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Alector, Inc.
• Alnylam Pharmaceuticals, Inc.
• Antisense Therapeutics Limited
• Arrowhead Pharmaceuticals, Inc.
• Biogen
• Bio-Path Holdings
• Dicerna Pharmaceuticals, Inc.
• Geron Corporation (Geron)
• GSK plc
• iCo Therapeutics Inc.
• Ionis Pharmaceuticals, Inc.
• ProQR Therapeutics
• Roche Holding AG
• Sarepta Therapeutics
• Sterna Biologicals

Overall world revenue for Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 in terms of value the market will surpass US$6,000.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 report help you?
In summary, our 280+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 Market, with forecasts for therapeutic application, ASO chemistry, and route of administration, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 24 key national markets – See forecasts for the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 15 of the major companies involved in the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Antisense Oligonucleotide (ASO) Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Developments in the Field of Target Specific Precision Medicine Driving the ASO Therapeutics Market
3.2.1.2 Adoption of ASO Therapeutics for the Treatment of Rare Diseases Driving the ASO Therapeutics Market
3.2.1.3 Improved Delivery Systems Helps in Unlocking the Full Potential of ASOs, thereby Boosting the Market
3.2.2 Market Restraining Factors
3.2.2.1 Off-target Effects Might Act as a Significant Market Restraint in the Development and Adoption of ASO Therapeutics
3.2.2.2 Potential Immunogenicity Response in Some Patients Might Restrain the ASO Therapeutics Market Growth
3.2.2.3 High Cost of Treatment and Manufacturing of ASO Therapeutics Might Impact the Market Growth Negatively
3.2.3 Market Opportunities
3.2.3.1 Novel Approach to Cancer Therapy Might Offer a Promising Market Opportunity to ASO Therapeutics
3.2.3.2 Pipeline Expansion Stands as a Significant Market Opportunity Within the Realm of ASO Therapeutics
3.2.3.3 In the Field of ASO Therapeutics, the Availability of Regulatory Support is a Significant Market Potential
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis

4 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by Therapeutic Application
4.1 Key Findings
4.2 Therapeutic Application Segment: Market Attractiveness Index
4.3 Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
4.4 Neurological Disorders
4.4.1 Market Size by Region, 2023-2033 (US$ Million)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Genetic Disorders
4.5.1 Market Size by Region, 2023-2033 (US$ Million)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Oncological Disorders
4.6.1 Market Size by Region, 2023-2033 (US$ Million)
4.6.2 Market Share by Region, 2023 & 2033 (%)
4.7 Cardiovascular Diseases
4.7.1 Market Size by Region, 2023-2033 (US$ Million)
4.7.2 Market Share by Region, 2023 & 2033 (%)
4.8 Others
4.8.1 Market Size by Region, 2023-2033 (US$ Million)
4.8.2 Market Share by Region, 2023 & 2033 (%)

5 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by ASO Chemistry
5.1 Key Findings
5.2 ASO Chemistry Segment: Market Attractiveness Index
5.3 Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
5.4 DNA Based ASO
5.4.1 Market Size by Region, 2023-2033 (US$ Million)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 RNA Based ASO
5.5.1 Market Size by Region, 2023-2033 (US$ Million)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Gapmer ASO
5.6.1 Market Size by Region, 2023-2033 (US$ Million)
5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by Route of Administration
6.1 Key Findings
6.2 Route of Administration Segment: Market Attractiveness Index
6.3 Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
6.4 Pulmonary Delivery
6.4.1 Market Size by Region, 2023-2033 (US$ Million)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Intravenous Injections
6.5.1 Market Size by Region, 2023-2033 (US$ Million)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Intradermal Injections
6.6.1 Market Size by Region, 2023-2033 (US$ Million)
6.6.2 Market Share by Region, 2023 & 2033 (%)
6.7 Intraperitoneal Injections
6.7.1 Market Size by Region, 2023-2033 (US$ Million)
6.7.2 Market Share by Region, 2023 & 2033 (%)
6.8 Topical Delivery
6.8.1 Market Size by Region, 2023-2033 (US$ Million)
6.8.2 Market Share by Region, 2023 & 2033 (%)
6.9 Others
6.9.1 Market Size by Region, 2023-2033 (US$ Million)
6.9.2 Market Share by Region, 2023 & 2033 (%)

7 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast

8 North America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
8.1 Key Findings
8.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
8.3 North America Antisense Oligonucleotide (ASO) Therapeutics Market .by Country, 2023, 2028 & 2033 (US$ Million)
8.4 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
8.5 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
8.6 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
8.7 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
8.8 U.S. Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
8.9 Canada Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

9 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
9.1 Key Findings
9.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
9.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Market by Country, 2023, 2028 & 2033 (US$ Million)
9.4 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
9.5 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
9.6 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
9.7 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
9.8 Germany Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
9.9 France Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
9.10 UK Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
9.11 Italy Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
9.12 Spain Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
9.13 Russia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
9.14 Rest of Europe Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

10 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market analysis
10.1 Key Findings
10.2 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
10.3 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market by Country, 2023, 2028 & 2033 (US$ Million)
10.4 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
10.5 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
10.6 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
10.7 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
10.8 Japan Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
10.9 China Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
10.10 India Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
10.11 Australia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
10.12 South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
10.13 Singapore Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
10.14 Rest of Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

11 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
11.1 Key Findings
11.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
11.3 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market .by Country, 2023, 2028 & 2033 (US$ Million)
11.4 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
11.5 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
11.6 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
11.7 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
11.8 Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
11.9 Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
11.10 Argentina Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
11.11 Colombia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
11.12 Rest of Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

12 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
12.1 Key Findings
12.2 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
12.3 MEA Antisense Oligonucleotide (ASO) Therapeutics Market by Country, 2023, 2028 & 2033 (US$ Million)
12.4 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
12.5 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
12.6 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
12.7 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
12.8 GCC Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
12.9 South Africa Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
12.10 Rest of MEA Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

13 Company Profiles
13.1 Competitive Landscape, 2022
13.2 Strategic Outlook
13.3 Biogen
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2017-2022
13.3.3.2 Gross Profit, 2017-2022
13.3.3.3 R&D, 2017-2022
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 Bio-Path Holdings
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Product Benchmarking
13.4.4 Strategic Outlook
13.5 Ionis Pharmaceuticals, Inc.
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2017-2022
13.5.3.2 Gross Profit, 2017-2022
13.5.3.3 R&D, 2017-2022
13.5.4 Product Benchmarking
13.5.5 Strategic Outlook
13.6 ProQR Therapeutics
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Product Benchmarking
13.6.4 Strategic Outlook
13.7 Sarepta Therapeutics
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2017-2022
13.7.3.2 Gross Profit, 2017-2022
13.7.3.3 R&D, 2017-2022
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 Alnylam Pharmaceuticals, Inc.
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis
13.8.3.1 Net Revenue, 2017-2022
13.8.3.2 Gross Profit, 2017-2022
13.8.3.3 R&D, 2017-2022
13.8.4 Product Benchmarking
13.8.5 Strategic Outlook
13.9 Arrowhead Pharmaceuticals, Inc.
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2017-2022
13.9.3.2 Gross Profit, 2017-2022
13.9.3.3 R&D, 2017-2022
13.9.4 Product Benchmarking
13.9.5 Strategic Outlook
13.10 GSK plc
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis
13.10.3.1 Net Revenue, 2017-2022
13.10.3.2 Gross Profit, 2017-2022
13.10.3.3 R&D, 2017-2022
13.10.4 Product Benchmarking
13.11 Geron Corporation (Geron)
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2017-2022
13.11.3.2 R&D, 2017-2022
13.11.4 Product Benchmarking
13.12 Antisense Therapeutics Limited
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2017-2022
13.12.3.2 R&D, 2017-2022
13.12.4 Product Benchmarking
13.12.5 Strategic Outlook
13.13 Sterna Biologicals
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Product Benchmarking
13.14 Alector, Inc.
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Product Benchmarking
13.14.4 Strategic Outlook
13.15 Dicerna Pharmaceuticals, Inc.
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Product Benchmarking
13.16 iCo Therapeutics Inc.
13.16.1 Company Snapshot
13.16.2 Company Overview
13.16.3 Product Benchmarking
13.17 Roche Holding AG
13.17.1 Company Snapshot
13.17.2 Company Overview
13.17.3 Financial Analysis
13.17.3.1 Net Revenue, 2017-2022
13.17.3.2 R&D, 2017-2022
13.17.4 Product Benchmarking

14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1 Antisense Oligonucleotide (ASO) Therapeutics Market Snapshot, 2023 & 2033 (US$ Million, CAGR %)
Table 2 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 7 Neurological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 8 Genetic Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 9 Oncological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 10 Cardiovascular Diseases Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 11 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 12 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 13 DNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 14 RNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 15 Gapmer ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 16 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 17 Pulmonary Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 18 Intravenous Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 19 Intradermal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 20 Intraperitoneal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 21 Topical Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 22 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 23 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 24 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 25 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 26 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 27 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 28 U.S. Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 29 Canada Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 30 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 31 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 32 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 33 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 34 Germany Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 35 France Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 36 UK Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 37 Italy Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 38 Spain Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 39 Russia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 40 Rest of Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 41 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 42 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 43 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 44 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 45 Japan Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 46 China Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 47 India Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 48 Australia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 49 South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 50 Singapore Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 51 Rest of Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 52 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 53 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 54 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 55 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 56 Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 57 Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 58 Argentina Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 59 Colombia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 60 Rest of Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 61 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 62 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 63 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 64 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 65 GCC Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 66 South Africa Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 67 Rest of MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 68 Strategic Outlook
Table 69 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Biogen: Product Benchmarking
Table 71 Biogen: Strategic Outlook
Table 72 Bio-Path Holdings: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Bio-Path Holdings: Product Benchmarking
Table 74 Bio-Path Holdings: Strategic Outlook
Table 75 Ionis Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Ionis Pharmaceuticals, Inc.: Product Benchmarking
Table 77 Ionis Pharmaceuticals, Inc.: Strategic Outlook
Table 78 ProQR Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 ProQR Therapeutics: Product Benchmarking
Table 80 ProQR Therapeutics: Strategic Outlook
Table 81 Sarepta Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Sarepta Therapeutics: Product Benchmarking
Table 83 Sarepta Therapeutics: Strategic Outlook
Table 84 Alnylam Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Alnylam Pharmaceuticals, Inc.: Product Benchmarking
Table 86 Alnylam Pharmaceuticals, Inc.: Strategic Outlook
Table 87 Arrowhead Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Arrowhead Pharmaceuticals, Inc.: Product Benchmarking
Table 89 Arrowhead Pharmaceuticals, Inc.: Strategic Outlook
Table 90 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 GSK plc: Product Benchmarking
Table 92 Geron Corporation (Geron): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Geron Corporation (Geron): Product Benchmarking
Table 94 Antisense Therapeutics Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Antisense Therapeutics Limited: Product Benchmarking
Table 96 Antisense Therapeutics Limited: Strategic Outlook
Table 97 Sterna Biologicals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Sterna Biologicals: Product Benchmarking
Table 99 Alector, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Alector, Inc.: Product Benchmarking
Table 101 Alector, Inc.: Strategic Outlook
Table 102 Dicerna Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Dicerna Pharmaceuticals, Inc.: Product Benchmarking
Table 104 iCo Therapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 iCo Therapeutics Inc.: Product Benchmarking
Table 106 Roche Holding AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Roche Holding AG: Product Benchmarking

List of Figures
Figure 1 Antisense Oligonucleotide (ASO) Therapeutics Market Segmentation
Figure 2 Antisense Oligonucleotide (ASO) Therapeutics Market by Therapeutic Application: Market Attractiveness Index
Figure 3 Antisense Oligonucleotide (ASO) Therapeutics Market by ASO Chemistry: Market Attractiveness Index
Figure 4 Antisense Oligonucleotide (ASO) Therapeutics Market by Route of Administration: Market Attractiveness Index
Figure 5 Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index by Region
Figure 6 Antisense Oligonucleotide (ASO) Therapeutics Market: Market Dynamics
Figure 7 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): “V” Shaped Recovery
Figure 8 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): “U” Shaped Recovery
Figure 9 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): “W” Shaped Recovery
Figure 10 Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %): “L” Shaped Recovery
Figure 11 Antisense Oligonucleotide (ASO) Therapeutics Market: Porter’s Five Forces Analysis
Figure 12 Antisense Oligonucleotide (ASO) Therapeutics Market: PEST Analysis
Figure 13 Antisense Oligonucleotide (ASO) Therapeutics Market by Therapeutic Application: Market Attractiveness Index
Figure 14 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 15 Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023, 2028, 2033 (%)
Figure 16 Neurological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 17 Neurological Disorders Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 18 Genetic Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 19 Genetic Disorders Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 20 Oncological Disorders Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 21 Oncological Disorders Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Cardiovascular Diseases Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 23 Cardiovascular Diseases Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 25 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Antisense Oligonucleotide (ASO) Therapeutics Market by ASO Chemistry: Market Attractiveness Index
Figure 27 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 28 Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023, 2028, 2033 (%)
Figure 29 DNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 30 DNA Based ASO Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 31 RNA Based ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 32 RNA Based ASO Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 33 Gapmer ASO Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 34 Gapmer ASO Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 35 Antisense Oligonucleotide (ASO) Therapeutics Market by Route of Administration: Market Attractiveness Index
Figure 36 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 37 Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023, 2028, 2033 (%)
Figure 38 Pulmonary Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 39 Pulmonary Delivery Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 40 Intravenous Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 41 Intravenous Injections Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 42 Intradermal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 43 Intradermal Injections Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 44 Intraperitoneal Injections Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 45 Intraperitoneal Injections Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 46 Topical Delivery Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 47 Topical Delivery Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 48 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 49 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 50 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Region 2023 and 2033 (Revenue, CAGR%)
Figure 51 NASH DNA Based ASO & Therapeutics Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 52 NASH DNA Based ASO & Therapeutics Market by Region, 2023-2033 (US$ Million, AGR %)
Figure 53 North America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 54 North America Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 55 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 56 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 57 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 58 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 59 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 60 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 61 North America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 62 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 63 U.S. Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 64 Canada Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 65 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 66 Europe Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 67 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 68 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 69 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 70 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 71 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 72 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 73 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 74 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 75 Germany Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 76 France Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 77 UK Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 78 Italy Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 79 Spain Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 80 Russia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 81 Rest of Europe Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 82 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 83 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 84 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 85 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 86 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 87 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 88 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 89 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 90 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 91 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 92 Japan Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 93 China Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 94 India Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 95 Australia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 96 South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 97 Singapore Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 98 Rest of Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 99 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 100 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 101 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 102 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 103 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 104 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 105 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 106 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 107 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 108 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 109 Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 110 Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 111 Argentina Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 112 Colombia Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 113 Rest of Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 114 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
Figure 115 MEA Antisense Oligonucleotide (ASO) Therapeutics Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 116 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 117 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Country, 2023 & 2033 (%)
Figure 118 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Therapeutic Application, 2023-2033 (US$ Million, AGR %)
Figure 119 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Therapeutic Application, 2023 & 2033 (%)
Figure 120 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by ASO Chemistry, 2023-2033 (US$ Million, AGR %)
Figure 121 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by ASO Chemistry, 2023 & 2033 (%)
Figure 122 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast by Route of Administration, 2023-2033 (US$ Million, AGR %)
Figure 123 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 124 GCC Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 125 South Africa Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 126 Rest of MEA Antisense Oligonucleotide (ASO) Therapeutics Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 127 Antisense Oligonucleotide (ASO) Therapeutics Market: Company Share/Ranking, 2022
Figure 128 Biogen: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 129 Biogen: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 130 Biogen: R&D, 2017-2022 (US$ Million, AGR %)
Figure 131 Ionis Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 132 Ionis Pharmaceuticals, Inc.: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 133 Ionis Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 134 Sarepta Therapeutics: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 135 Sarepta Therapeutics: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 136 Sarepta Therapeutics: R&D, 2017-2022 (US$ Million, AGR %)
Figure 137 Alnylam Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 138 Alnylam Pharmaceuticals, Inc.: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 139 Alnylam Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 140 Arrowhead Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 141 Arrowhead Pharmaceuticals, Inc.: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 142 Arrowhead Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 143 GSK plc: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 144 GSK plc: Gross Profit, 2017-2022 (US$ Million, AGR %)
Figure 145 GSK plc: R&D, 2017-2022 (US$ Million, AGR %)
Figure 146 Geron Corporation (Geron): Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 147 Geron Corporation (Geron): R&D, 2017-2022 (US$ Million, AGR %)
Figure 148 Antisense Therapeutics Limited: Net Revenue, 2017-2022 (US$ Thousand, AGR%)
Figure 149 Antisense Therapeutics Limited: R&D, 2017-2022 (US$ Thousand, AGR%)
Figure 150 Roche Holding AG: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 151 Roche Holding AG: R&D, 2017-2022 (US$ Million, AGR %)

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（生化学的薬物）の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（administration）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

アンチセンスオリゴヌクレオチド（ASO）治療薬市場レポート：2023-2033

サマリー

目次

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（生化学的薬物）の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（administration）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?